1. Home
  2. WTI vs TRDA Comparison

WTI vs TRDA Comparison

Compare WTI & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo W&T Offshore Inc.

WTI

W&T Offshore Inc.

HOLD

Current Price

$3.60

Market Cap

446.3M

Sector

Energy

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.77

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTI
TRDA
Founded
1983
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
446.3M
481.6M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
WTI
TRDA
Price
$3.60
$11.77
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.00
AVG Volume (30 Days)
9.8M
190.2K
Earning Date
03-16-2026
05-07-2026
Dividend Yield
1.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$487,096,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$4.93
52 Week High
$3.82
$13.99

Technical Indicators

Market Signals
Indicator
WTI
TRDA
Relative Strength Index (RSI) 64.88 48.68
Support Level $1.67 $10.78
Resistance Level $3.82 $12.56
Average True Range (ATR) 0.27 0.80
MACD 0.01 -0.11
Stochastic Oscillator 91.55 28.60

Price Performance

Historical Comparison
WTI
TRDA

About WTI W&T Offshore Inc.

W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: